{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:12:07Z","timestamp":1791331927467,"version":"4.3.1"},"reference-count":66,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T00:00:00Z","timestamp":1383523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent advances in biological therapies have proved highly effective in treating psoriasis and other inflammatory conditions, including psoriatic arthritis, rheumatoid arthritis, inflammatory bowel disease and ankylosing spondylitis. However, adverse effects related to their immunosuppression have been observed, including an increased propensity to viral infections. This review evaluates the evidence of herpes zoster (<jats:styled-content style=\"fixed-case\">HZ<\/jats:styled-content>) risk from biologics based on clinical reports, cohort studies and randomized controlled studies. The risk of <jats:styled-content style=\"fixed-case\">HZ<\/jats:styled-content> associated with these agents remains controversial, especially when comparing their risk with non\u2010biological therapy used to treat the same inflammatory conditions. This review specifically assesses the risk of the <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> inhibitors etanercept, adalimumab and infliximab, as well as interleukin\u201012\/23 inhibitor ustekinumab. We found multiple cohort studies, randomized controlled trials and case reports that suggest infliximab increases risk of <jats:styled-content style=\"fixed-case\">HZ<\/jats:styled-content>, whereas adalimumab, etanercept and ustekinumab <jats:styled-content style=\"fixed-case\">HZ<\/jats:styled-content> risk remain controversial. Nevertheless, <jats:styled-content style=\"fixed-case\">HZ<\/jats:styled-content> vaccination should be considered prior to initiation of biological therapy, particularly infliximab.<\/jats:p>","DOI":"10.1111\/jdv.12307","type":"journal-article","created":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T09:36:41Z","timestamp":1383557801000},"page":"846-852","source":"Crossref","is-referenced-by-count":54,"title":["The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions"],"prefix":"10.1111","volume":"28","author":[{"given":"L.","family":"Adelzadeh","sequence":"first","affiliation":[{"name":"David Geffen School of Medicine at UCLA Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Jourabchi","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology Kaiser Permanente Los Angeles Medical Center Los Angeles CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,11,4]]},"reference":[{"key":"e_1_2_5_2_1","first-page":"367","article-title":"Biologic therapy in psoriasis: a brief history. II","volume":"68","author":"Tutrone WD","year":"2001","journal-title":"Cutis"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.120568"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041320"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2005.02143.x"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.4.2721"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071094"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06009.x"},{"key":"e_1_2_5_9_1","unstructured":"Abbot Laboratories North Chicago IL. Adalimumab (Humira)package insert;2004."},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1396-0296.2004.04044.x"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20072066"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2005.10.003"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200425677"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-008-9233-0"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.12.7948"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1496"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2007.10.011"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810652"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.07.034"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67763-X"},{"key":"e_1_2_5_23_1","first-page":"1177","article-title":"Once weekly administration of etanercept 50\u00a0mg is efficacious and well tolerated in patients with moderate\u2010to\u2010severe plaque psoriasis: a randomized controlled trial with open\u2010label extension","volume":"159","author":"Kerkhof PC","year":"2008","journal-title":"Br J Dermatol"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.12.1627"},{"key":"e_1_2_5_25_1","first-page":"1845","article-title":"Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double\u2010blind, placebo\u2010controlled multicenter trial","volume":"125","author":"Yang HZ","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04954-0"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.02.021"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"e_1_2_5_29_1","first-page":"31","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1\u00a0year in the treatment of moderate\u2010to\u2010severe plaque psoriasis","volume":"6","author":"Menter A","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.384"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00748.x"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.027"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08315.x"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2011.05.005"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01347.x"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11015.x"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0511"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10615.x"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1086\/598331"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430150071008"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel328"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.146"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201108"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.383"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.062760"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1159\/000338691"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.125658"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04230.x"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1099"},{"key":"e_1_2_5_51_1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1684\/ejd.2011.1424","article-title":"Protracted herpes zoster and severe postherpetic neuralgia after inadvertant infliximab administration","volume":"21","author":"Failla V","year":"2011","journal-title":"Europ J Dermatol"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2010.551302"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/0009922810380452"},{"key":"e_1_2_5_54_1","first-page":"374","article-title":"Brachial plexitis and myelitis and herpes\u2010zoster lumbar plexus disorder in patient treated with infliximab","volume":"20","author":"Arias M","year":"2005","journal-title":"Neurologia"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31819bca9e"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2007.03481.x"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/pmj.2003.014373"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.7.661"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1159\/000232389"},{"key":"e_1_2_5_60_1","first-page":"277","article-title":"Varicella zoster virus infection in patients taking the TNF\u2010alpha inhibitor, etanercept: coincidence or causal?","volume":"68","author":"Izumi A","year":"2009","journal-title":"Hawaii Med J"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1159\/000323736"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70227-5"},{"key":"e_1_2_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.10.001"},{"key":"e_1_2_5_64_1","first-page":"1","article-title":"Prevention of herpes zoster","volume":"50","author":"Harpaz R","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051016"},{"key":"e_1_2_5_66_1","first-page":"1","article-title":"Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","journal-title":"MMWR"},{"key":"e_1_2_5_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7304"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12307","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12307","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12307","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T11:53:59Z","timestamp":1695556439000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,4]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1111\/jdv.12307"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12307","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,4]]}}}